Table 1. Characteristics of individual study.
| First(author) | Year | Region | No.of patiens (female) | Ages mean (SD) | Design | Classification of urinary incontinence | Basic diseases | Intervention | Follow-up (weeks) |
|---|---|---|---|---|---|---|---|---|---|
| Schurch [41] | 2005 | Switzerland | 59 (23) | 41 | Randomized, doubled-blind | NDO | MS:6, SCI:53 | Group 1: BTX-A 300U (19)Group 2: BTX-A 200U (19) Group 3: Placebo (21) |
6 |
| Dmochowski [34] | 2010 | USA | 313 (288) | 58.8 | Randomized, doubled-blind | IOAB | NA | Group 1: BTX-A 50U (56) Group 2: BTX-A 100U (55) Group 3: BTX-A 150U (50) Group 4: BTX-A 200U (52) Group 5: BTX-A 300U(55) Group 6: Placebo (43) |
NA |
| Cruz [33] | 2011 | Portugal | 275 (155) | 46(13.1), 44.4(13.9), 46.9(13.4) |
Randomized, doubled-blind | NDO | MS:154, SCI:121 | Group 1: BTX-A 200U(92) Group 2: BTX-A 300U(91) Group 3: Placebo (92) |
2, 6, 12 |
| Rovner [40] | 2011 | USA | 313 (288) | 58.8 | Randomized, doubled-blind | IOAB | NA | Group 1: BTX-A 50U(57) Group 2: BTX-A 100U(54) Group 3: BTX-A 150U(49) Group 4: BTX-A 200U(53) Group 5: BTX-A 300U(56) Group 6: Placebo (44) |
12, 36 |
| Denys [22] | 2012 | France | 199 (87) | 62.3, 61.7 | Randomized, doubled-blind | IOAB | NA | Group 1: BTX-A 50U(23) Group 2: BTX-A 100U(23) Group 3: BTX-A 150U(30) Group 4: Placebo (31) |
12 |
| Ginsberg [36] | 2012 | USA | 416 (245) | 46(13) | Randomized, doubled-blind | NDO | MS:227, SCI:189 |
Group 1: BTX-A200U(135) Group 2: BTX-A300U(127) Group 3: Placebo (145) |
6 |
| Ginsberg [35] | 2013 | USA | 381 (311) | 49.7(12.1), 49.9(10.7), 50.2(10.7) |
Randomized, doubled-blind | NDO | MS:381, SCI:310 | Group 1: BTX-A 200U(227) Group 2: BTX-A 300U(223) Group 3: Placebo (241) |
6 |
| Nitti [38] | 2013 | USA | 557 (497) | 61.7(12.7), 61(13.1) | Randomized, doubled-blind | IOAB | NA | Group 1: BTX-A100U (278) Group 2: Placebo (272) |
12 |
| Rovner [39] | 2013 | USA | 691(400) | 45.9, 45.6, 46.2 | Randomized, doubled-blind | NDO | MS:103, SCI:138 | Group 1: BTX-A 200U(227) Group 2: BTX-A 300U(223) Group 3: Placebo (241) |
6 |
| Kennelly [37] | 2013 | USA | 387 (233) | 46.4 | Randomized, doubled-blind | NDO | SCI, MS | Group 1: BTX-A 300U(185) Group 2: BTX-A 200U(202) |
6 |
| Abdelwahab [32] | 2015 | Egypt | 80 (63) | 31.35, 30.22 | Randomized, doubled-blind | IOAB | NA | Group 2: BoNTA 200U (40) Group 1: BTX-A 100U (40) |
12, 36 |
NDO: Neurogenic detrusor overactivity, IDO: Idiopathic detrusor overactivity, MS: Multiple sclerosis, SCI: Spinal cord injury, BTX-A: Botulinum toxin A, NA: Not available.